Production (Stage)
Kiora Pharmaceuticals, Inc.
KPRX
$3.08
-$0.01-0.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 16.00M | 16.00M | 16.00M | 16.00M |
| Total Other Revenue | 20.00K | 20.00K | 20.00K | 20.00K | -- |
| Total Revenue | 20.00K | 16.02M | 16.02M | 16.02M | 16.00M |
| Cost of Revenue | 1.42M | 570.00K | 1.40M | 1.17M | 1.66M |
| Gross Profit | -1.40M | 15.45M | 14.62M | 14.85M | 14.34M |
| SG&A Expenses | 5.74M | 5.54M | 5.10M | 5.13M | 4.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.70M | 10.44M | 9.93M | 9.73M | 9.77M |
| Operating Income | -9.68M | 5.58M | 6.09M | 6.29M | 6.23M |
| Income Before Tax | -9.86M | 5.66M | 5.64M | 3.29M | 2.90M |
| Income Tax Expenses | 2.19M | 2.07M | 90.30K | 90.30K | 90.30K |
| Earnings from Continuing Operations | -12.05 | 3.59 | 5.55 | 3.20 | 2.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.05M | 3.59M | 5.55M | 3.20M | 2.81M |
| EBIT | -9.68M | 5.58M | 6.09M | 6.29M | 6.23M |
| EBITDA | -9.67M | 5.60M | 6.12M | 6.32M | 6.27M |
| EPS Basic | -2.86 | 2.32 | 0.61 | -6.55 | -13.17 |
| Normalized Basic EPS | -1.25 | 1.93 | 0.72 | -0.77 | -4.68 |
| EPS Diluted | -2.86 | 1.12 | -0.60 | -7.76 | -14.38 |
| Normalized Diluted EPS | -1.25 | 1.18 | -0.04 | -1.53 | -5.43 |
| Average Basic Shares Outstanding | 16.82M | 15.49M | 12.10M | 8.68M | 4.87M |
| Average Diluted Shares Outstanding | 16.82M | 16.50M | 13.11M | 9.69M | 5.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |